Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HealthCentral.com

This article was originally published in The Tan Sheet

Executive Summary

Fourth quarter net sales of $14.7 mil. mark a 23% increase over Q3 performance, Emeryville, Calif.-based e-tailer announces Jan. 11. Prior-year revenues of $8.9 mil. were not based on e-commerce sales, which began January 2000, firm explains. HealthCentral - which last year acquired more.com, Vitamins.com and DrugEmporium.com and launched WebRx.com - has recorded its third consecutive quarter of reduced day-to-day operating expenses, which it estimates at $9 mil. for the quarter, excluding non-recurring items. Complete sales and earnings are slated for early February release. Firm's shares rose 7.7% on early sales news, closing at .44 Jan. 12; NASDAQ notified HealthCentral Jan. 5 that it has until April 4 to comply with rules regarding stocks below $1 before delisting procedures begin

You may also be interested in...



HealthCentral.com Third Quarter Break-Even Predicted

HealthCentral.com's operations will break even before October, Chairman and CEO Albert Greene predicted in a Feb. 14 analysts call.

HealthCentral.com Third Quarter Break-Even Predicted

HealthCentral.com's operations will break even before October, Chairman and CEO Albert Greene predicted in a Feb. 14 analysts call.

HealthCentral.com Third Quarter Break-Even Predicted

HealthCentral.com's operations will break even before October, Chairman and CEO Albert Greene predicted in a Feb. 14 analysts call.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel